A New Option for Severe Nerve Pain in Type 1 Diabetes: What One Case Study Shows

Painful diabetic peripheral neuropathy—chronic nerve pain affecting the legs and feet—is a common and debilitating complication of diabetes. Beyond the pain itself, it disrupts sleep, limits mobility, and significantly reduces quality of life. While medications like gabapentin and amitriptyline are standard treatments, many patients find these drugs don't provide adequate relief.

A 19-year-old with a 9-year history of Type 1 diabetes came to Mzuzu Central Hospital in Malawi with severe bilateral lower-limb pain that had worsened over three years. She described burning and stabbing sensations, numbness, and heightened pain sensitivity (a condition called allodynia). Her pain score was 8 out of 10, and conventional medications—amitriptyline, gabapentin, vitamin B supplements, diclofenac, and tramadol—had failed to help.

Between May 15 and May 25, 2026, she underwent four ultrasound-guided lumbar sympathetic blocks, a procedure in which medication is injected near nerves in the lower spine to block pain signals. After the first procedure, her pain dropped from 8 to 4. After the second, it fell to 1. She reported complete pain relief before the case report concluded.

This report documents the first use of this particular procedure at this hospital for this condition—a meaningful milestone in expanding pain management options in under-resourced settings. The immediate results in this patient are encouraging.

However, this is a single case, not a clinical trial testing the procedure across many patients. One person's dramatic response doesn't prove the technique works reliably for everyone with diabetic nerve pain, nor does it tell us how long relief lasts or how often procedures might be needed. More research involving larger numbers of patients would be needed to establish safety and effectiveness.

Advanced pain management techniques—including the lumbar sympathetic block, radiofrequency ablation, and neuromodulation—are not widely available in many parts of the world. This case highlights both the potential of these approaches and the gap in access for people living with diabetes in low-resource healthcare settings. For patients exhausted by standard medications, such options may offer hope, but availability remains a significant barrier.

Source: Malawi medical journal : the journal of Medical Association of Malawi. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.